StockTipsArenaBeta

BUY Torrent Pharmaceuticals Limited — Shrikant Chouhan, Kotak Securities

BUYTorrent Pharmaceuticals Limited

byShrikant Chouhan, Kotak SecuritiesHorizon: NA (inferred Swing (≤2wk))19 Aug 2026via ET Now

Entry₹5,044.5Inferred
Target₹5,130
Total upside +1.69% (call closed)
Stop loss₹4,980-1.28% risk
Exit₹4,98020 Aug 2026, 10:15 am
Stop-loss hit-1.28%
Follow Shrikant Chouhan for new calls(31% target hit, 64 closed calls)Get alertsWatch TORNTPHARM for new buy/sell callsGet alertsSee 129 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 20 Aug 2026
3 supporting2 neutral0 opposing
Supports the BUY call (3)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·19 Aug · today

Torrent Pharma Shares Trade Higher After Q1 Results

NewsGoogle News·17 Aug · 2d ago

(opens in new tab)

Torrent Pharma షేర్లు జోరు: Q1 ఫలితాల తర్వాత ఇన్వెస్టర్ల ఆసక్తి

NewsGoogle News·17 Aug · 2d ago

(opens in new tab)
Neutral / worth noting (2)

Torrent Pharma Share: Q1 முடிவுகள்! வருவாய் ஜோர், லாபம் மிதமோ?

NewsGoogle News·17 Aug · 2d ago

(opens in new tab)

Torrent Pharma assigned ESG rating of 70 by NSE Sustainability

NewsGoogle News·11 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.